Turnstone Biologics Corp. (TSBX)

Turnstone Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	19.31	73.3	101.29
Revenue Growth (YoY)	-	-	-73.66%	-27.64%	-
Cost of Revenue	56.93	56.93	60.38	79.68	53.08
Gross Profit	-56.93	-56.93	-41.08	-6.38	48.21
Selling, General & Admin	16.3	16.39	17.85	18.22	13.55
Operating Expenses	4.86	16.39	17.85	18.22	13.55
Operating Income	-61.79	-73.32	-58.92	-24.61	34.66
Other Non Operating Income (Expenses)	-2.02	1.69	3.55	0.93	0.71
EBT Excluding Unusual Items	-63.82	-71.62	-55.38	-23.67	35.37
Other Unusual Items	0.82	0.82	-0.11	-7.02	-1.67
Pretax Income	-62.99	-70.8	-55.49	-30.69	33.7
Income Tax Expense	0.02	0.04	-0.29	0.14	0.43
Net Income	-63.01	-70.84	-55.2	-30.83	33.27
Preferred Dividends & Other Adjustments	-	-	0.04	0.19	29.79
Net Income to Common	-63.01	-70.84	-55.24	-31.02	3.48
Shares Outstanding (Basic)	23	23	12	2	2
Shares Outstanding (Diluted)	23	23	12	2	3
Shares Change (YoY)	38.81%	99.23%	365.39%	-7.96%	-
EPS (Basic)	-2.73	-3.07	-4.78	-12.49	1.62
EPS (Diluted)	-2.73	-3.07	-4.78	-12.49	1.28
Free Cash Flow	-	-67.67	-67.4	-76.23	-49.04
Free Cash Flow Per Share	-	-2.94	-5.83	-30.68	-18.16
Gross Margin	-	-	-212.76%	-8.71%	47.59%
Operating Margin	-	-	-305.21%	-33.57%	34.22%
Profit Margin	-	-	-286.12%	-42.33%	3.44%
Free Cash Flow Margin	-	-	-349.12%	-104.00%	-48.41%
EBITDA	-60.01	-71.48	-56.13	-20.71	36.05
EBITDA Margin	-	-	-290.71%	-28.25%	35.59%
D&A For EBITDA	1.78	1.84	2.8	3.9	1.39
EBIT	-61.79	-73.32	-58.92	-24.61	34.66
EBIT Margin	-	-	-	-33.57%	34.22%
Effective Tax Rate	-	-	-	-	1.28%

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q